Evaluation of cardiovascular risk by growth-differentiation factor-15 and tissue Doppler imaging in children with subclinical hypothyroidism

被引:5
|
作者
Arslan, Derya [1 ]
Buyukinan, Muammer [2 ]
Uysal, Celil [3 ]
Deniz, Cigdem Damla [4 ]
机构
[1] Konya Training & Res Hosp, Univ Hlth Sci, Dept Pediat Cardiol, Konya, Turkey
[2] Konya Training & Res Hosp, Dept Pediat Endocrinol, Konya, Turkey
[3] Patnos State Hosp, Dept Pediat, Agri, Turkey
[4] Konya Training & Res Hosp, Dept Biochem, Konya, Turkey
关键词
Subclinical hypothyroidism; Cardiovascular risk; GDF-15; Child; HEART-FAILURE; GUIDELINES; ECHOCARDIOGRAPHY; ASSOCIATION; CHILDHOOD; HORMONE; DISEASE;
D O I
10.1007/s12020-019-01933-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Subclinical hypothyroidism, defined as increased TSH serum levels and normal serum free T4 concentrations, has been associated with an increased risk of heart disease in adults. But, data in children and adolescents are scanty and treatment of subclinical hypothyroidism is controversial. Growth differentiation factor-15 (GDF-15) is a promising biomarker of cardiac remodeling. This study aimed to evaluate the cardiovascular risk factors in children with subclinical hypothyroidism, measured with tissue Doppler echocardiography (TDE), and conventional echocardiography and GDF-15 level. Methods The study comprised a total of 41 pediatric patients with subclinical hypothyroidism (SH) (mean age 9.6 +/- 4.7 years) and 31 healthy children (mean age 11.2 +/- 3.4 years) as the control group. Subclinical hypothyroidism was defined as a thyroid-stimulating hormone level higher than 4 mIU/l and a normal free-thyroxine level (0.6-1.8 ng/dl). Tissue Doppler echocardiography was performed to all individuals in the control group and patient group at the beginning of the study. Global systolic function as assessed by left ventricular ejection fraction was compared between groups. The serum GDF-15 level was measured. Results There were no significant differences in demographic parameters between the SH and control groups. The left ventricular internal diameter end systole, interventricular septal end diastole, left ventricular posterior wall end diastole, and tricuspid annular plane systolic excursion values were significantly different between the SH and control groups (p = 0.038, 0.028, 0.005, and 0.000, respectively). The mean mitral isovolumic relaxation time value of the SH group was 57.2 +/- 9.3 ms, compared to 44.5 +/- 5.6 ms for the control group (p = 0.000). The mean tricuspid isovolumic contraction time value of the SH group was 58.7 +/- 9.4 ms, and that of the control group was 45.1 +/- 5.3 ms (p = 0.000). The mean tricuspid isovolumic relaxation time value of the SH group was 58.03 +/- 9.5 ms, and that of the control group was 45.1 +/- 5.3 ms (p = 0.000). There were no significant differences in the other m-mode or pulse Doppler echocardiography values between two groups. The GDF-15 value of the SH group was 382.6 +/- 268.2 pg/mL, and that of the control group was 473.6 +/- 337.9 pg/mL; this difference was not significant. Conclusion Patients with subclinical hypothyroidism versus healthy individuals had some changes in echocardiographic parameters that indicate involvement of diastolic function of the left ventricle. They were significantly different when compared SH group and the control group. This study demonstrated ventricle diastolic dysfunction in pediatric patients with hypothyroidism. The results of our study suggest that cardiac follow-up may be useful in patients with subclinical hypothyroidism and clinical trials are needed to explore therapeutic effects of T4 and T3 administration in this patients.
引用
收藏
页码:601 / 607
页数:7
相关论文
共 50 条
  • [41] Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases
    di Candia, Angelo Michele
    de Avila, Diane Xavier
    Moreira, Gustavo Rodolfo
    Villacorta, Humberto
    Maisel, Alan S.
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2021, 9
  • [42] Association of Growth Differentiation Factor-15 With Event Cause and Cardiovascular Failure After Pediatric Cardiac Arrest in a Multi-Institutional Trial
    Herrmann, Jeremy R. R.
    Jackson, Travis C. C.
    Fabio, Anthony
    Clark, Robert S. B.
    Berger, Rachel P. P.
    Janesko-Feldman, Keri L. L.
    Kochanek, Patrick M. M.
    Fink, Ericka L. L.
    POCCA Investigators
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (15):
  • [43] Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome Observations From PROVE IT-TIMI 22
    Bonaca, Marc P.
    Morrow, David A.
    Braunwald, Eugene
    Cannon, Christopher P.
    Jiang, Songtao
    Breher, Stephanie
    Sabatine, Marc S.
    Kempf, Tibor
    Wallentin, Lars
    Wollert, Kai C.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (01) : 203 - 210
  • [44] Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy
    Lajer, Maria
    Jorsal, Anders
    Tarnow, Lise
    Parving, Hans Henrik
    Rossing, Peter
    DIABETES CARE, 2010, 33 (07) : 1567 - 1572
  • [45] Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study
    Hagstrom, Emil
    James, Stefan K.
    Bertilsson, Maria
    Becker, Richard C.
    Himmelmann, Anders
    Husted, Steen
    Katus, Hugo A.
    Steg, Philippe Gabriel
    Storey, Robert F.
    Siegbahn, Agneta
    Wallentin, Lars
    EUROPEAN HEART JOURNAL, 2016, 37 (16) : 1325 - 1333
  • [46] The impact of growth differentiation factor 15 on the risk of cardiovascular diseases: two-sample Mendelian randomization study
    Wang, Zhuo
    Yang, Fangkun
    Ma, Menghuai
    Bao, Qinyi
    Shen, Jinlian
    Ye, Feiming
    Xie, Xiaojie
    BMC CARDIOVASCULAR DISORDERS, 2020, 20 (01)
  • [47] Limited incremental value of growth differentiation factor 15 in the initial evaluation of low and intermediate risk acute chest pain patients
    Karaji, Iman
    Steiro, Ole-Thomas
    Myrmel, Gard M. S.
    Omland, Torbjorn
    Tjora, Hilde L.
    Langorgen, Jorund
    Bjorneklett, Rune
    Skadberg, Oyvind
    Bonarjee, Vernon V. S.
    Mjelva, Oistein R.
    Collinson, Paul
    Vikenes, Kjell
    Larsen, Terje H.
    Aakre, Kristin M.
    Pedersen, Eva Ringdal
    CLINICAL BIOCHEMISTRY, 2025, 137
  • [48] Growth differentiation factor-15 predicts all-cause death and major adverse cardiovascular events in patients with coronary heart disease: a prospective cohort study
    Lyu, Lyu
    Xv, Cui
    Xu, Juan
    Liu, Zhenzhen
    He, Yanru
    Zhu, Wenjing
    Lin, Lin
    Yang, Qiang
    Wei, Yun
    Wang, Jinda
    Huang, Taoke
    Hao, Benchuan
    Liu, Hongbin
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, : 1109 - 1121
  • [49] Growth Differentiation Factor 15 Predicts Cancer Death in Patients With Cardiovascular Risk Factors: The J-HOP Study
    Negishi, Keita
    Hoshide, Satoshi
    Shimpo, Masahisa
    Kario, Kazuomi
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [50] Association between Growth Differentiation Factor 15 (GDF15) and Cardiovascular Risk in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
    Shin, Min Young
    Kim, Ji Min
    Kang, Yea Eun
    Kim, Min Kyeong
    Joung, Kyong Hye
    Lee, Ju Hee
    Kim, Koon Soon
    Kim, Hyun Jin
    Ku, Bon Jeong
    Shong, Minho
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2016, 31 (09) : 1413 - 1418